ABSTRACT: A prototype rapid antigen test for the on-site detection of respiratory syncytial virus (RSV) infection was developed and evaluated. The platform uses instrumented assay analysis, eliminating potential operator bias in the interpretation of the test result that may occur with visually interpreted rapid antigen assays. The device was tested as the first point-of-care (POC) infectious disease application of novel reporter up-converting phosphor technology (UPT) using a specifically designed portable UPT reader (UPlink TM ) . Assays were performed by mixing nasopharyngeal specimen with RSV-specific UPT reporter particles and addition of the mixture to a disposable cassette containing a lateral flow (LF) strip with RSV capture antibodies. UPT reporters bound on the specific capture zone were analyzed with the UPlink reader. Reproducibility testing of the UPlink-RSV (UPR) test by naïve users confirmed the potential of UPlink for POC applications where testing is not always performed by highly trained medical staff. The performance of UPR was further evaluated with clinical nasopharyngeal specimens. A prospective study at an independent test site demonstrated clinical parameters of 90% sensitivity and 98.3% specificity with an overall correlation of 96.2% as compared to viral culture with RT-PCR verification. These results are in agreement with in-house retrospective studies and results obtained with other available commercial rapid antigen assays.
INTRODUCTION
Respiratory syncytial virus (RSV) is an enveloped, RNA virus of the Paramyxoviridae family. It is a frequent cause of serious lower respiratory tract disease in young children. 1 RSV bronchiolitis is a severe illness caused by RSV; if not treated it can become life-threatening in infants (as compared to adults) with small peripheral airways. In addition, RSV is a major cause of severe pneumonia in young children. RSV outbreaks occur yearly, usually during winter months, and it is recommended that health care providers consider RSV as the cause of acute respiratory symptoms. RSV is contagious and easy to transfer through casual contact, making hospital staff frequent vectors for viral transmission. Thus rapid diagnosis of patients requiring hospital admission is important not only to guide in therapeutic decisions, but also to prevent nosocomial RSV transmission and thus eventually reduce medical costs. 2, 3 Cell culture is still considered the gold standard for detection of RSV. However, for rapid diagnosis, cultivation of the virus is impractical because of the relatively long incubation needed. In addition, diagnosis of acute infection may be difficult on account of the insensitivity of viral culture. 4 In this respect, reverse transcriptase-polymerase chain reaction (RT-PCR) is a better alternative. 5 The various RT-PCR methods available for clinical laboratories can provide results within a few hours. 6 However, despite the much shorter turnaround time as compared to that of viral culture, RT-PCR has its limitations for point-of-care (POC) testing. In general, specimens requiring RT-PCR analysis are collected and batch-processed or are sent to commercial laboratories. Consequently, RT-PCR as well as viral culture is merely used to confirm the results from rapid antigenz tests.
Currently, there are a few FDA-cleared rapid RSV antigen assays available in the United States. These immunoassay-based POC devices are standardized assays convenient for analysis of single samples in the POC environment. However, the current rapid assays require visual interpretation of the test result, whereas assays that minimize operator interpretation are preferred because they reduce the chance of human error. In this article we describe a prototype UPlink assay for the detection of RSV-in nasopharyngeal wash specimens (UPlink-RSV, UPR). The UPlink system comprises a portable reader with a built-in IR (infrared) laser and immunoassay devices (disposable cassettes containing test-specific LF strips). For UPR, the LF strips are RSV-specific. The reader scans LF strips in the immunoassay devices and displays the results such that subjective interpretation of the test by the operator is eliminated. The basis of the UPlink platform is the up-converting phosphor technology (UPT), an ultrasensitive reporter particle technology. 7 These reporters, upon excitation by IR light, up-convert the energy (two-photon up-conversion) to give a visible 550-nm green emission. Since no biological specimen in nature up-converts low-energy IR light, UPT applications are unaffected by specimen background and display excellent signal-to-noise ratios.
The objective of this study was to evaluate the performance of UPR (UPlink-RSV) compared to viral culture. Samples that generated discrepant results were also evaluated by RT-PCR. The RT-PCR results were considered decisive as this method is accepted as more sensitive than viral culture. 9 For comparison, the same samples were also analyzed with Directigen RSV (DIR; Becton Dickinson Franklin Lakes, NJ, USA), another rapid antigen detection assay.
MATERIALS AND METHODS

UPlink Platform-Detection of UPT Reporters
The existing UPlink analyzer (OraSure Technologies, Bethlehem, PA, USA) was originally developed for on-site testing of drugs of abuse in oral samples. It uses a low-power (1.0-watt) IR laser that interrogates UPT-deposited lateral flow (LF) strips. The LF strip is an integrated part of the disposable plastic cassette, a self-contained immunoassay device that is inserted into the UPlink analyzer (FIG. 1A) . The analyzer is a general UPT reader with integrated software that can be modified to suit various test applications. It detects localized deposition of the UPT reporters by reading the visual light emitted upon IR excitation; the emission signal is measured and computed as relative fluorescence units (RFU). The UPlink analyzer is provided with a bar code scanner that identifies the unique assay associated with each cassette.
UPlink-RSV (UPR) Assay Development
LF strips for UPR were stripped with a test line composed of RSV monoclonal antibodies against the F, G, and N antigens (FIG. 1B) . A flow-control line containing a noncontagious RSV isolate (FRhKy, Viral Antigens Inc., Memphis, TN, USA) was stripped downstream from the test line to verify migration of the UPT conjugate through the LF strip. The strips were assembled as described earlier. 10 A set of anti-F and anti-N antibodies different from the antibodies stripped on the test line were conjugated with UPT reporter particles. These reporter antibodies allow effective immuno-sandwich formation with the antibodies on the test line through RSV antigen. Conjugations were performed according to standard procedures as described earlier. 11 Freezedried pellets of UPT conjugates, so-called lyospheres (Biolyph LLC, Hopkins, MN, USA) were produced and stored in vacuum-sealed glass vials (FIG. 1C) .
UPR Assay Procedure
The UPR test was performed by mixing assay buffer and specimen with the lyophilized reporter (lyosphere) in a glass vial followed by addition of the mixture to the test cassette (FIG. 1C) . The cassette is inserted into the portable UPlink analyzer to scan and interpret the test result. The overall time of the assay is 15 min. In detail, the UPR test procedure consists of four steps: (1) addition of 100-L sample treatment buffer (STB at pH 8.2 containing TrisHCl, NaCl, EDTA, specific detergents, and ProClin 950) to a vial containing one UPT-lyosphere; (2) addition of 200-L sample (nasopharyngeal wash) to the above mixture; (3) transfer of the entire mixture to the sample reservoir of the UPR cassette to initiate lateral LF and allow the signal to develop for 12 min; and (4) scanning of the cassette using the UPlink reader. All specimens generating signals above the predetermined cut-off value were considered RSVpositive. The cut-off threshold value was determined on the basis of 86 frozen specimens, which were RSV-negative by viral culture. The resulting cut-off threshold value of 9,801 RFU was calculated as the average test peak area value plus twice the standard deviation. Tests were determined invalid if there was no signal generated at the flow-control line (FIG. 1D) . Data were stored in the UPlink reader and can be transferred to a personal computer. The reader display shows the result as RSV+, RSV-, or invalid control.
Blinded UPR Reproducibility Study with Inexperienced Operators
To study the accuracy and the reproducibility of the UPR assay, four specimens spiked with different levels of RSV (a mixture of ATCC VR-1302 and VR-1400) were tested by three naïve operators from different sites over three consecutive days. For every operator, three sets (one set for each day of testing) of specimens were prepared. Each set was composed of: (1) M4 transport medium (Remel. Inc., Lenexa, KS, USA) without RSV; (2) M4 spiked with RSV at 2.8 × 10 2 TCID 50 /mL; (3) M4 spiked with RSV at 5.6 × 10 2 TCID 50 /mL; and, (4) M4 spiked with RSV at 1.1 × 10 3 TCID 50 /mL. These samples were designated as negative, low positive, medium positive, and high positive, respectively. Specimens in the first set (test day 1) were labeled 1-4, specimens in the second set (test day 2) were labeled 5-8, and the specimens in the third set (test day 3) were labeled 9-12. The order of the negative, low-, medium-, and high-positive sample was randomized for the 3 days of testing. All tests were performed in replicates of five.
Evaluation of UPR versus DIR at an Independent Clinical Test Site (Prospective Study)
Sample Collection
A series of 78 samples was collected and tested at the Providence Health System (PHS) in Portland, Oregon. Samples were collected and immediately analyzed over a period of 3 months (January through March). Phosphate-buffered saline nasopharyngeal wash specimens were collected from patients suspected of having RSV infection following the standard collection method as described in the package insert of BD Directigen RSV. Samples were transported on ice to the laboratory for testing. Only specimens that were refrigerated at 2-8
• C for <12 h were evaluated. A portion of each specimen was aliquoted immediately after collection and transferred into M4 media for viral culture testing. Hence, samples were never frozen prior to rapid antigen testing and initiation of viral culture. Unused portions of all specimens were labeled and frozen at −20
• C in case a nucleic acid verification test was required.
Laboratory Methods
Laboratory methods included antigen testing with UPlink-RSV (UPR, OraSure Technologies), Directigen-RSV (DIR, Becton Dickinson), and viral culture with DFA detection. Viral culture was performed according to standard protocols established at the test site and antigen assays were performed according to the protocol provided by the manufacturers. Interpretation of the DIR test results was carried out according to the manufacturer's guidelines. In this method, specimens were reported positive, negative, or indeterminate (invalid control) by visual reading of the test result. For UPR, UPlink-displayed test results (RSV+, RSV-, or invalid control) were used.
RT-PCR Verification
RT-PCR was performed on frozen specimens. All samples requiring verification were transported on dry ice to special facilities at the Children's Hospital Medical Center (CHMCC) in Cincinnati. A standard RT-PCR detection protocol suited for the detection of RSV A and B strains was used to analyze the specimens.
Statistical Analysis
UPR and DIR test results were analyzed independently. Clinical samples were considered true positives or true negatives in all cases where antigen assay results were in agreement with viral culture. When assay results and viral culture were discrepant, samples were further tested by RT-PCR. The RT-PCR results were regarded as decisive.
RESULTS
The automated analysis of the UPR assay eliminates subjective interpretation of the test results, since the software integrated in the UPlink reader determines whether the test result is positive, negative, or invalid. Reproducibility of UPR was evaluated by repetitive testing of blinded specimens with variable amounts of spiked RSV (four concentration levels). Experiments performed by three independent naïve operators indicated an overall concordance of 95% (TABLE 1) . The operators performed 60 tests each over a period of three consecutive days (20 tests a day), with a concordance of 100%, 90%, and 95% for operators 1, 2, and 3, respectively. The day-to-day concordance was 98.3%, 95%, and 91.7% for the first, second, and third day, respectively. Each of the four RSV concentration levels was tested 45 times by the three operators together with a concordance of 93.3%, 88.9%, 97.8%, and 100% for the negative, low-positive, medium-positive, and high-positive samples, respectively. For an independent clinical evaluation of UPR (prospective study), a total of 78 fresh samples was gathered and tested at the PHS in Portland, Oregon. All samples were collected from patients suspected of having RSV infection; 56% of the samples were obtained from infants or children below 2 years of age. After collection, the specimens were tested within 12 h (specimens were not frozen but kept refrigerated until testing) using UPR, DIR, and viral culture.
The results from UPR and DIR tests were independently compared against the viral culture test. The comparison indicated 9 discrepant results; 4 discrepancies for UPR versus culture and 5 discrepancies for DIR versus culture (TABLE 2). These 9 discrepancies relate back to 6 viral cultures: 3 culture results discrepant with both rapid assays, 2 culture results discrepant with DIR only, and 1 culture result discrepant with UPR only. The six cultures with discrepant rapid assay results were subjected to RT-PCR verification. Among these samples only one specimen showed disagreement between culture and RT-PCR results: a negative culture result tested positive upon RT-PCR verification. After resolving the status of the discrepant samples, the clinical parameters for both UPR and DIR analysis were calculated (TABLE 2) . 
DISCUSSION
UPR is the first UPT/UPlink application. The LF-based assay screens for active RSV infections using nasopharyngeal specimens and is capable of detecting viable as well as nonviable RSV fragments from A and B type RSV strains. Sensitive and chemically inert 400-nm phosphorescent UPT particles are applied as reporter in UPR. The reporter is readily detected with UPlink, a fully automated inexpensive portable reader developed especially for on-site and POC testing. This automation entails that UPR assay results are presented as "RSV+" "RSV-," or "invalid control." It omits potentially operator-biased assay interpretation that can occur with DIR and other commonly used rapid antigen tests that rely on visual interpretation of the assay.
Reproducibility testing of the UPR assay and its developed standard test protocol was performed by three naïve operators and resulted in an overall concordance of 95%. This demonstrated that the whole procedure worked well enough to allow utilization by inexperienced users. The lowest level of agreement (88.9%) was obtained when testing a low-positive sample. This could be the result of small procedural alterations or mistakes, which will have the relatively largest effect when testing low-positive samples as their signals are closest to the predetermined threshold. Further acquaintance and experience with the whole procedure (including transport, storage, and the actual UPR assay) can be expected to have a positive impact on concordance. Testing of the high-positive sample resulted in 100% concordance.
An evaluation with 78 fresh clinical samples (56% from infants below the age of 6 months) was performed at an independent test site. RT-PCR-resolved analysis demonstrated clinical parameters of 90%, 98.3%, 94.7%, 96.6%, and 96.2% for UPR against 80%, 100%, 100%, 93.5%, and 94.8% for DIR, regarding sensitivity, specificity, positive predictive value, negative predictive value, and overall correlation, respectively. In fact, the performance of both assays with this set of fresh samples was almost similar. Out of 78 clinical samples tested, DIR scored 4 false negatives, whereas for UPR the score included 2 false negatives and 1 false positive.
CONCLUSION
On the basis of data presented in this article, we conclude that the UPR test as described here has considerable potential in the rapid diagnosis of RSV bronchiolitis and RSV-caused pneumonia. A large clinical study is required to determine whether the overall performance of UPR is better than other rapid RSV antigen-based immunoassays. However, significant added value of UPR is found in the automated analysis of the test (provided by the UPlink platform) eliminating any operator-biased interpretation of the result. The UPR test protocol is simple and robust, allowing application in POC settings by less-trained naïve personnel. Moreover, future versions of the test platform will provide fully integrated devices that only require operator interaction for addition of the clinical specimen to the disposable test device.
